Cyclin-Dependent Kinase Synthetic Lethality Partners in DNA Damage Response

被引:10
|
作者
Kciuk, Mateusz [1 ,2 ]
Gielecinska, Adrianna [1 ]
Mujwar, Somdutt [3 ]
Mojzych, Mariusz [4 ]
Kontek, Renata [1 ]
机构
[1] Univ Lodz, Dept Mol Biotechnol & Genet, Banacha 12-16, PL-90237 Lodz, Poland
[2] Univ Lodz, Doctoral Sch Exact & Nat Sci, Banacha St 12-16, PL-90237 Lodz, Poland
[3] Maharishi Markandeshwar Deemed Univ Mullana, MM Coll Pharm, Ambala 133207, India
[4] Siedlce Univ Nat Sci & Humanities, Dept Chem, 3 Maja 54, PL-08110 Siedlce, Poland
关键词
cyclin-dependent kinase (CDK); DNA damage response (DDR); inhibitor; MYC oncogene; poly (ADP-ribose) polymerase 1 (PARP-1); synthetic lethality; POLY(ADP-RIBOSE) POLYMERASE PARP; C-MYC; GENOMIC INSTABILITY; BREAST-CANCER; CELL LYMPHOMA; P53; REPLICATION; INHIBITION; CDK1; APOPTOSIS;
D O I
10.3390/ijms23073555
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cyclin-dependent kinases (CDKs) are pivotal mediators and effectors of the DNA damage response (DDR) that regulate both the pathway components and proteins involved in repair processes. Synthetic lethality (SL) describes a situation in which two genes are linked in such a way that the lack of functioning of just one maintains cell viability, while depletion of both triggers cell death. Synthetic lethal interactions involving CDKs are now emerging, and this can be used to selectively target tumor cells with DNA repair defects. In this review, SL interactions of CDKs with protooncogene products MYC, poly (ADP-ribose) polymerase (PARP-1), and cellular tumor antigen p53 (TP53) are discussed. The individual roles of each of the SL partners in DDR are described.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] INHIBITORS OF CYCLIN-DEPENDENT KINASE AND CANCER
    BIGGS, JR
    KRAFT, AS
    JOURNAL OF MOLECULAR MEDICINE-JMM, 1995, 73 (10): : 509 - 514
  • [32] Cyclins, Cyclin-Dependent Kinases, and Cyclin-Dependent Kinase Inhibitors in the Mouse Nervous System
    Grison, Alice
    Atanasoski, Suzana
    MOLECULAR NEUROBIOLOGY, 2020, 57 (07) : 3206 - 3218
  • [33] Cyclins, Cyclin-Dependent Kinases, and Cyclin-Dependent Kinase Inhibitors in the Mouse Nervous System
    Alice Grison
    Suzana Atanasoski
    Molecular Neurobiology, 2020, 57 : 3206 - 3218
  • [34] Cyclin-dependent kinase inhibitors and hepatocarcinogenesis
    Hui, AM
    Sakamoto, M
    Kanai, Y
    Ino, Y
    Gotoh, M
    Hirohashi, S
    RECENT ADVANCES IN GASTROENTEROLOGICAL CARCINOGENESIS I, 1996, : 481 - 485
  • [35] Cyclin-dependent kinase 9-cyclin K functions in the replication stress response
    Yu, David S.
    Zhao, Runxiang
    Hsu, Emory L.
    Cayer, Jennifer
    Ye, Fei
    Guo, Yan
    Shyr, Yu
    Cortez, David
    EMBO REPORTS, 2010, 11 (11) : 876 - 882
  • [36] Expression of cyclin-dependent kinase 6, but not cyclin-dependent kinase 4, alters morphology of cultured mouse astrocytes
    Ericson, KK
    Krull, D
    Slomiany, P
    Grossel, MJ
    MOLECULAR CANCER RESEARCH, 2003, 1 (09) : 654 - 664
  • [37] CYCLINS AND CYCLIN-DEPENDENT KINASES - TAKE YOUR PARTNERS
    PINES, J
    TRENDS IN BIOCHEMICAL SCIENCES, 1993, 18 (06) : 195 - 197
  • [38] Re: Preclinical and clinical development of cyclin-dependent kinase modulators - Response
    Senderowicz, AM
    Sausville, EA
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (14) : 1185 - 1185
  • [39] Cyclins, cyclin-dependent kinases, cyclin-dependent kinase inhibitors and their role in head and neck cancer
    Jeannon, JP
    Wilson, JA
    CLINICAL OTOLARYNGOLOGY, 1998, 23 (05): : 420 - 424
  • [40] Changes in the activity of cyclin-dependent kinase 2 and cyclin-dependent kinase 5 accompany differentiation of rat primary oligodendrocytes
    Tang, XM
    Cambi, F
    Strocchi, P
    MOLECULAR BIOLOGY OF THE CELL, 1997, 8 : 120 - 120